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Abstract
The CXCL4 paralog CXCL4L1 is a less studied chemokine that
has been suggested to exert an antiangiogenic function. However,
CXCL4L1 is also expressed in patient tumors, tumor cell lines, and
murine xenografts, promptingamoredetailedanalysis of its role in
cancer pathogenesis. We used genetic and antibody-based
approaches to attenuate CXCL4L1 in models of pancreatic ductal
adenocarcinoma (PDAC). Mechanisms of expression were
assessed in cell coculture experiments, murine, and avian xeno-
transplants, including through an evaluation of CpGmethylation
and mutation of critical CpG residues. CXCL4L1 gene expression
was increased greatly in primary and metastatic PDAC. We found
that myoﬁbroblasts triggered cues in the tumor microenviron-
ment,which led to inductionofCXCL4L1 in tumor cells.CXCL4L1
expression was also controlled by epigenetic modiﬁcations at
critical CpG islands, which were mapped. CXCL4L1 inhibited
angiogenesis but also affected tumor development more directly,
dependingon the tumor cell type. In vivo administrationof anmAb
against CXCL4L1 demonstrated a blockade in the growth of
tumors positive for CXCR3, a critical receptor for CXCL4 ligands.
Our ﬁndings deﬁne a protumorigenic role in PDAC development
for endogenous CXCL4L1, which is independent of its antiangio-
genic function. Cancer Res; 76(22); 6507–19. !2016 AACR.
Introduction
A paralog of CXCL4, named platelet factor variant-1 (PF4v1)
or CXCL4L1, was identiﬁed in 1989, but its role in cancer
progression has not yet been investigated (1, 2). CXCL4L1 and
CXCL4 exhibit only 34% differences in the amino terminus
encoding the signal sequence and 4.3% difference in the mature
protein. CXCL4L1 has been shown to be more potent than
CXCL4 at inhibiting cell proliferation and migration (2, 3).
Furthermore, inhibition of tumor development was observed
in tumors derived from implantation of A549, LLC, and B16
cells in mice, treated with recombinant CXCL4L1 (1). In addi-
tion, the secretion and processing mechanisms of CXCL4L1 and
CXCL4 are different (4). However, both chemokines are secret-
ed with similar efﬁciency (3). CXCL4L1 has much lower glycan-
binding afﬁnity and better diffusibility in vitro and in vivo (3).
These differences are caused by single amino acid changes,
which confer a unique structure to the molecule (3, 5).
CXCL4L1 is not only expressed in the platelet megakaryocytic
lineage but also in immune cells and in other cell types as well,
such as smooth muscle cells and endothelial cells (4). It has
been reported that CXCL4L1 interacts with CXCR3B and that its
blockade in vivo using speciﬁc anti-CXCR3 mAbs abrogates the
inhibitory effect of CXCL4L1 on corneal angiogenesis in the
mouse (6–8). CXCR3 is also expressed in a variety of cell types,
including immune cells, vascular cells, and tumor cells. CXCR3
exists as different isoforms, including CXCR3-A, CXCR-B, and
CXCR3-alt (7). CXCR3-A has been implicated in chemotactic
activity and is highly expressed in Th1-type CD4þ T cells,
effector CD8þ T cells, and natural killer cells and exhibits
tumor-promoting abilities (9). CXCR3-B, which differs from
CXCR3-A by an amino terminal extension, is believed to
mediate angiostatic activities (7). These ﬁndings suggest that
CXCL4L1 has regulatory functions in tumor angiogenesis.
Although some data have been published on the effect of
exogenous full-length CXCL4L1 or of a CXCL4L1 C-terminal
fragment in subcutaneous tumor models (1, 6, 10–12), nothing
is known about its precise role in controlling tumor growth and
invasion. We provide herein the ﬁrst study, to our knowledge, of
the regulation of CXCL4L1 expression and the role of endogenous
CXCL4L1 in tumor development using pancreatic ductal adeno-
carcinoma (PDAC) as a tumor model. Furthermore, the results
described in this article are also of clinically relevance.
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Pancreatic tumor cell lines (BxPC3 ATCC CRL-1687), Panc-1
ATCC CRL-1469, MIA PaCa-2 ATCC CRL-1420), human oste-
osarcoma MG63 cells (ATCC CRL-1427), U87 cell line (ATCC-
HTB-14), human umbilical vein endothelial cells (HUVEC,
Lonza), human coronary artery smooth muscle cells (SMC,
PromoCell), NIH3T3 cells (ATCC CRL-1658), Hek cells (ATCC
CRL-1573), human hepatic myoﬁbroblasts (kindly donated by
J. Rosenbaum, INSERM U 1034, University Bordeaux, Pessac,
France) were grown as described in Supplementary Materials
and Methods. The last cell authentication was carried out by
PCR single-locus technology (Euroﬁns, GE, date of report:
October 14, 2015).
BxPC3 Panc-1 and MIA PaCa-2 tumor cells were transduced
with recombinant lentiviral vectors expressing ﬁreﬂy luciferase.
Tumor cell implantation in fertilized chicken eggs (Gallus
gallus) was handled as described previously (13, 14). Tumor
nodule isolation, processing for microarrays, and subsequent
analysis are described in ref. 14 and in Supplementary Materials
and Methods.
Coculture experiments
BxPC3 cells or PANC-1 cells were cocultured with human liver
myoﬁbroblast, HUVEC, or SMC. BxPC3 cells were cocultured for
24 to 96 hours with myoﬁbroblasts on PEN membrane. Laser
capture microdissection analyses were performed by using a
PALM MicroBeam microdissection system version 4.0–1206
equipped with a P.A.L.M. RoboSoftware (P.A.L.M. Microlaser
Technologies, Zeiss). Furthermore, coculture experiments using
transwell system (Greiner Bio-One <0.45 mm) with BxPC3 cells
andmyoﬁbroblastswere used. These experimentswere conducted
in twoways. Tumor cells (2"105)were placed in theupper side of
the membrane and myoﬁbroblasts at the lower side in DMEM
containing 20% FBS. Alternatively, myoﬁbroblasts were removed
after 24 hours and RNA extracted after additional 24 hours and
CXCL4L1 expression measured. For details, see Supplementary
Materials and Methods.
Isolation of microparticles
Microparticles were isolated from supernatants of myoﬁbro-
blasts grown to conﬂuency (T75 at conﬂuency). Centrifugation
was done at 2,500 rpm for the elimination of cellular fragments
(10minutes). The supernatant was centrifuged at 100,000" g for
1 hour, and the pellet was collected and resuspended in medium
before use.
In vivo mouse models
To evidence tumor targeting of MabL1, the antibody was
labeled with IRDye and 25 mg of labeled antibodies was
injected into the tail vein of mice with subcutaneous BxPC3
tumors or with metastasis after spreading of BxPC3 cells
through the portal vein following intrasplenic injection accord-
ing to standard procedures (15). At different times post-injec-
tion, animals were imaged with the Odyssey Imaging System
(LI-COR).
For xenograft models, 8-week-old mice were anaesthetized
with intraperitoneal injection of ketamine (150 mg/kg) and
xylazine (15 mg/kg) and xenografted with 3 " 106, 1 " 106,
and 3.75 " 105 BxPC3, Panc-1, or MIA PaCa-2 cells stably
transfected with a luciferase reporter gene in 100 mL serum-free
medium by subcutaneous, intrapancreatic, and intrasplenic
injection, respectively. Treatment with MabL1 antibody was
carried according to standard procedures (15). Tumor volumes
were measured by caliper or bioluminescence (Photon Imager,
Biospace Lab). For more details, see Supplementary Materials
and Methods.
All other methods were carried out according to standard
procedures (references below) and are detailed in the Supple-
mentary Materials and Methods. These include reagents; siRNA
transfection with Lipofectamine (Invitrogen, according to the
manufacturer's instructions); cell proliferation and invasion
assay (16); Western blotting and immunoprecipitation
(17, 18); RNA extraction and semiquantitative and quantitative
RT-PCR (18); histology, IHC, and tissue microarray (TMA;
refs. 18); in situ hybridization (Roche RNA Labeling Kit SP6/T7,
according to the manufacturer's instructions), labeling of
MabL1 (IRDye 800CW, Protein Labeling Kit-HighMW#928-
38040, LI-COR); construction of luciferase reporter vectors
luciferase reporter assay (Promega, according to the manufac-
turer's instructions); in vitro methylation of plasmid DNA and
bisulﬁte sequencing (New England Biolabs, according to the
manufacturer's instructions); and clearance kinetic of MabL1
conjugated to IRDye or biotin.
In silico and statistical analysis
In silico online research was done on Oncomine (https://www.
oncomine.org) and The Cancer Genome Atlas (TCGA; cancergen-
ome.nih.gov) datasets.
Experimental data. Results are presented as mean # SEM. Statis-
tical signiﬁcance was determined by a one-tailed, unpaired Stu-
dent t test using Prism 5.03GraphPad Software. For the TMAs, the
statistical analysis was performed by using a Kruskal–Wallis test,
followed by Dunn multiple comparison procedure. P < 0.05 was
considered signiﬁcant ($$$, <0.001; $$, <0.01; $, <0.05).
Ethical issues
Male RAG-g/c mice were housed and treated in the animal
facility of Bordeaux University (Animalerie Mutualis!ee Bor-
deaux). All animal procedures have been done according to the
institutional guidelines and approved by the local ethics
committee.
Fresh human adenocarcinoma samples were provided
by Prof. Martin Schilling (Klinik f€ur Allgemeine Chirurgie,
Viszeral-, Gef€aß- und Kinderchirurgie, Homburg, Germany).
Fresh tumor tissues were obtained during surgery and directly
snap-frozen in liquid nitrogen. TMAs were provided by Prof.
Anne Couvelard (Ho^pital Bichat, Paris, France). Patients gave
their consent prior tissue analysis according to the clinical
guidelines.
Results
Expression of CXCL4L1 or CXCL4 in pancreatic
adenocarcinoma
Transcriptomic proﬁling identiﬁes CXCL4L1 but not CXCL4 in the
PDAC-CAM model. Dual transcriptomic analysis using human
Affymetrix or chicken Affymetrix microarrays was performed
between tumor day 1 (T1) and tumor day 6 (T6) of BxPC3 cells
implanted onto the chick chorioallantoic membrane (CAM; E11
and E16 of embryonic development; ref. 14). CXCL4L1 was
Quemener et al.
Cancer Res; 76(22) November 15, 2016 Cancer Research6508
upregulated at T6 compared with T1 (a 14-fold increase) in
human Affymetrix arrays.
Real-time PCR (SYBR Green) revealed signiﬁcant CXCL4L1
expression in T6 tumors when compared with T1 CAM tumors
(9.7-fold). No expression was seen in BxPC3 cells in vitro
(Fig. 1A). When TaqMan for RT-PCR was used, a very small
amount of CXCL4 was detected in BxPC3 cells but only at
37 cycles (CT). CXCL4L1 was never detected in BxPC3 cells
cultured under these conditions.
An mAb (MabL1) speciﬁc for CXCL4L1 revealed immunore-
activity in T6 CAM tumors (Fig. 1B), and CXCL4L1 protein was
also detected by Western blotting (Fig. 1C). In situ hybridization
demonstrated CXCL4L1 but not CXCL4 expression in T6 CAM
tumors (Fig. 1D).
Expression analysis in mouse models of pancreatic carcinoma.
CXCL4L1 is expressed in BxPC3 tumors grown in mice (Fig. 1E,
left) in the primary tumor and lung metastasis (Fig. 1F, top). In
contrast to BxPC3, some CXCL4L1 expression was already
detected in Panc-1 cells in culture. However, similar to BxPC3,
expression was further increased (4.49-fold) when cells were
implanted into mice (Fig. 1E, middle and F, lower middle).
The effect of the microenvironment is speciﬁc to CXCL4L1
and does not occur for CXCL4. Furthermore, BxPC3 grafts
form lung micrometastases (average size: 0.024 mm2, n ¼ 10),
whereas Panc-1 grafts form larger metastases (average size:
0.15 mm2, n ¼ 8).
The situation was different for MIA PaCa-2, another PDAC
cell line (Fig. 1E and F, right). In this case, cells merely express
CXCL4, but not CXCL4L1, at signiﬁcant levels in vitro. In
xenograft tumors, CXCL4 was further increased and CXCL4L1
became detectable.
Thus, the expression proﬁle in vitro and in vivo is heterogeneous
in these three PDAC cell line.
Expression analysis of CXCL4L1/CXCL4 in human tumor samples.
CXCL4L1 is merely expressed in fetal liver, colon, and to some
extent in spleen; CXCL4 is highly expressed in spleen (Supple-
mentary Fig. S1A). Normal human pancreas comparatively does
not express elevated levels of CXCL4L1 or CXCL4 mRNA.
CXCL4L1 mRNA was overexpressed in 33 of 33 samples from
human PDAC patients (median log2 of 2.55 corresponding to a
median of 5.85; Supplementary Fig. S1B). CXCL4L1 protein
was detected in primary pancreatic tumors and metastasis
(Supplementary Fig. S1C–S1E). CXCL4 was expressed in
patient samples, but at lower expression levels than CXCL4L1
(Supplementary Fig. S1B right, and S1F).
In the TMA, increased CXCL4L1 immunoreactivity was signif-
icantly associated with pancreatic adenocarcinoma (P < 0.001;
Supplementary Fig. S1G–S1O). A statistically signiﬁcant increase
was also observed in adenosquamous tumors and chronic pan-
creatitis (P < 0.05).
CXCL4L1 expression is signiﬁcantly higher in PDAC in
comparison with control in the Segara Pancreatic statistics
(19). In the Stratford and Yeh dataset (GSE21501), survival
was signiﬁcantly linked to CXCL4L1 expression (P ¼ 0.023). In
the TCGA dataset (cancergenome.nih.gov), statistical signiﬁ-
cance was >0.05, probably due to the insufﬁcient amount of
patients included in the analysis (Supplementary Fig. S2).
The Ishikawa Pancreas statistics (20; left panel) was used to
compare CXCL4 gene expression in pancreas or in pancreatic
ductal adenocarcinoma. Survival analysis (right panel) did not
show a signiﬁcant link to survival in the TCGA pancreatic cancer
cohort (P ¼ 0.096; Supplementary Fig. S2).
Thus, these data suggest that tumor-derived CXCL4L1, but
not CXCL4, is a possible marker for the clinical evolution of
PDAC.
Cellular and molecular analysis of CXCL4L1 expression
We focused all of our subsequent analyses on CXCL4L1.
We reasoned that some microenvironmental cues could
induce CXCL4L1 expression. We therefore cocultured BxPC3
cells with endothelial cells (HUVECs, HUACs), human SMCs,
NIH 3T3 cells, or myoﬁbroblasts. None of the cell types was
able to induce CXCL4L1 expression in BxPC3 cells except
myoﬁbroblasts (Fig. 2A and B). For VAMP2, colocalization
was observed but to a lesser extent (Pearson coefﬁcient,
0.67; Fig. 2C).
Coculturing BxPC3 cells with myoﬁbroblasts in the transwell
system revealed signiﬁcant induction of CXCL4L1 in tumor cells.
Microparticles from the myoﬁbroblast-conditioned medium
(CM) were able to increase CXCL4L1 expression to some extent,
albeit much lower than the complete CM (Fig. 2D).
These results indicate that a paracrine factor derived from
myoﬁbroblasts is able to increase CXCL4L1 expression in tumor
cells. The majority of this factor is soluble and a fraction is also
contained in microparticles.
We also demonstrated that expression of CXCL4L1 is revers-
ible in BxPC3 cells after removal of myoﬁbroblasts from the
transwell chamber (Fig. 2E). However, coculturing myoﬁbro-
blasts with PANC-1 in the transwell system could not further
increase CXCL4L1 expression (Supplementary Fig. S3A). Thus,
myoﬁbroblasts may provide the initial trigger for CXCL4L1
expression, but additional factors may be required for full
stimulation.
Myoﬁbroblasts express, by their own, high levels of vimentin
and FAP and low levels of FSP1 and both chemokines (Supple-
mentary Fig. S3B).
We next focused on epigenetic modiﬁcations that might be
involved in CXCL4L1 expression. The CXCL4L1 gene is located
within a cluster of chemokines-encoded genes (Fig. 3A). To
determine the expression of these genes and to examine the
putative inﬂuence of CpG islands methylation, BxPC3 cells
were stimulated with 50-Aza, a potent DNA methyltransferase
inhibitor, and with or without the histone deacetylase inhib-
itor, trichostatin A (TSA; Fig. 3B). Treatment with 50Aza or TSA
increased the level of CXCL4L1 mRNA in BxPC3 cells (Fig. 3B,
left). In contrast, no changes were observed in CXCL1 and
CXCL6 expression with this treatment. This indicates that
DNA methylation is involved in the silencing of the CXCL4L1
gene in BxPC3 cells.
Using the MethPrimer website, one CpG island was found
to be located within the ﬁrst intron (Fig. 3C). Bisulﬁte sequenc-
ing indicated that two of eight sites (þ150, þ193, þ210, þ212,
þ 214, þ227, þ250, and þ259) were demethylated in the
presence of 50Aza [CpG 6 (þ227) and CpG 7 (þ250)], the CpG
site number referring to the transcription start site (Fig. 3D). All
7 sequences from the most hypomethylated lung metastasis
showed hypomethylation of the two CpG sites. Globally,
hypomethylation at CpG 6 and 7 was of 58.75% # 13.38 SD
(n ¼ 5 metastases). In the most hypomethylated subcutaneous
primary tumors, the majority of sequences (4/7) showed
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Figure 1.
CXCL4L1 expression in the PDAC-CAM and mouse xenograft model. A, CXCL4L1 expression in BxPC3 cells in vitro and in the PDAC-CAMmodel at day 1 (T1) and
day 6 (T6), normalized to S16 expression. CXCL4L1 mRNA at T1 with arbitrary value 1. B, immunolabeling on T6 CAM with MabL1. C, Western blotting
for CXCL4L1 from pooled T6 CAM lysates (n ¼ 3) or BxPC3 cells lysates with MabL1. The gel is representative of two independent experiments. D,
in situ hybridization of T6 PDAC-CAM samples with CXCL4L1 riboprobes. Dotted lines, tumor nodes; full lines, CAM surface. E, qRT-PCR from mRNA of
BXPC3, Panc-1, and MIA PaCa-2 cells in culture (n ¼ 4) or of tumors derived from subcutaneously injected cells (n ¼ 8 tumors; $$ , P < 0.01; $$$ , P < 0.001).
F, CXCL4L1 immunolabeling of BxPC3 (subcutaneous), Panc-1, and MIA PaCa-2 tumors (orthotopic) and lung metastasis. Global view (inset). Scale bars, 50 mm
(primary tumors) and 100 mm (lung metastasis). Error bars, SEM. $ , positive node.
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hypomethylation. However, this was not uniform for all
tumors examined and some variability was observed. Globally,
hypomethylation was of 25.09% # 4.45 SD (n ¼ 8 subcuta-
neous tumors). This correlates with the induction of expression
of CXCL4L1 (Fig. 3D, right).
In patients (n ¼ 10), for all 8 methylation sites, 69.38% # 4.9
SD hypomethylation was observed (Fig. 3D). For CpG 6 (þ227)
andCpG7 (þ250), this percentagewas of 74.60%#7.3 SD. Thus,
the majority of sequences demonstrate hypomethylation at site
CpG 6 (þ227) and CpG 7 (þ250), which is in agreement with
results observed with the cell line. It is to emphasize that DNA
from the entire tumor tissue was analyzed, which also includes
tumor stroma and some normal pancreatic tissue.
To determine whether CpG 6 (þ227) and CpG 7 (þ250) are
involved in the induction of CXCL4L1, CpG 6 (þ227) and
CpG 7 (þ250) were mutated (C!T). After in vitro methylation
followed by transfection, a Luc reporter assay was performed.
The ratio of LucF/LucR was highly increased when CpG
6 (þ227) and CpG 7 (þ250) were mutated when compared
with the nonmutated wild type (Fig. 3E).
Short-term stimulation with IL1b was unable to induce
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26.3 ± 1.02 No CT 19.41 ± 3.23 25.85 ± 1.48 No CT
11.4 ± 0.56 No CT 21.74 ± 5.58 31.63 ± 5.0 No CT
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Coculture of tumor cells with myoﬁbroblasts. A, immunoﬂuorescence staining for CXCL4L1 on BxPC3 cells alone (left) or cocultured for 4 days with
myoﬁbroblasts (MF; right). Blue, DAPI-labeled nuclei. B, qRT-PCR from laser microdissected BxPC3 cell mRNA. Data as CT value as means # SD of
ﬁve microdissected samples. HPRT1 as a housekeeping gene and a-SMA as a control for contamination by myoﬁbroblasts. C, immunoﬂuorescence
staining on cocultured BxPC3 for CXCL4L1 and VAMP-2. Blue, DAPI-labeled nuclei. Merged staining (yellow) revealed areas of colocalization and scatter 2D
plots of intensities in red and green immunoﬂuorescence channels (NIS software). D, BxPC3 cells (2 " 105) were cocultured using transwell system
with myoﬁbroblasts (2 " 105) for 24 hours or with microparticles. mRNA was extracted and analyzed by qPCR for CXCL4L1 expression. Data as copy
number/HPRT. Scale bar, 50 mm (A) and 10 mm (C). E, BxPC3 cells (2 " 105) were cocultured using a transwell system with myoﬁbroblasts (2 " 105) for
24 hours. Myoﬁbroblasts were then removed from the transwell chamber for 24 hours. mRNA was then extracted and analyzed by qPCR for CXCL4L1
expression. Data as copy number/HPRT. $$$ , P < 0.001.
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Modulation of CXCL4L1 expression by DNA methylation. A, CXCL4L1 and CXCL4 genomic organization. B, RT-PCR analyses of CXCL4, CXCL4L1, CXCL1, and
CXCL5 mRNA from BxPC3 cells treated with 50-Aza and/or TSA (left). RT-PCR analyses of CXCL4 and CXCL4L1 mRNA from platelets, BxPC3, and
MG63 cells treated with IL1b and 50-Aza/TSA (right). GAPDH as an internal control. C, location of CpG sites (vertical bars); bisulﬁte sequencing primers in
the ﬁrst intron with the MethPrimer website. D, methylation of CXCL4L1 in BxPC3 cells treated or untreated with 50-Aza in BxPC3 subcutaneous
primary tumors and in lung metastases from mice injected with BxPC3 into the spleen (one representative tumor and metastasis, n ¼ 10 tumors/group;
left). Filled and open circles, methylated and unmethylated CpG sites, respectively. qRT-PCR of CXCL4L11 mRNA from 50-Aza–treated or untreated
BxPC3 cells and from subcutaneous tumor and lung metastasis (right). HPRT1, internal control. (n ¼ 6 samples/group). E, characterization of CXCL4L1
expression. The 1-kb upstream promoter, exon 1, and intron 1 regions of human CXCL4L1 cloned in front of the luciferase ﬁreﬂy gene. Wild-type sequence
(WT) or mutated sequence in the two CpG sites regulated by the 50Aza treatment. After in vitro methylation and transfection, the ratio of LucFireﬂy/
LucRenilla was determined (n ¼ 3; $$ , P < 0.01). Error bars, SEM.
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observed in MG63 osteosarcoma cells (see Fig. 3B, right;
ref. 10). Long-term stimulation with IL1b was reported to
trigger demethylation (21) but was unable to increase
CXCL4L1 in PDAC.
Expression of CXCR3 in pancreatic adenocarcinoma
High expression of CXCR3-A mRNA was seen in Panc-1 cells
(Fig. 4A) but no expression in BXPC3 or MIA PaCa-2 cells.
Some CXCR3-B mRNA was detected in Panc-1 cells, and low
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Expression of CXCR3 in pancreatic adenocarcinoma. A, qRT-PCR for CXCR3-A and CXCR3-B. B, immunoﬂuorescence staining in vitro. C, qRT-PCR for
CXCR3-A and -B in primary tumors from BxPC3, PANC-1, and MIA PaCa-2 cells implanted mice (n ¼ 12 and 10 tumors/group). D, immunostaining for
human CXCR3 of subcutaneous BxPC3 and orthotopic PANC-1 and MIA PaCa-2 tumors (left) and lung metastasis (middle and right). E, IHC for CXCR3 (brown)
and hematoxylin counterstaining (blue) of PDAC patients' TMA showing apical (top left), cytoplasmic (top middle), membrane (top right), and nuclear
staining (bottom). Scale bars, 20 mm (B), 100 mm (D, left and bottom right), 500 mm (D, middle), and 50 mm (D, top right; E). Error bars, SEM.
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mRNA expression was also seen in BxPC3 and MIA PaCa-2
cells. However, no CXCR3 protein expression was seen in
BxPC3 and MIA PaCa-2 cells in vitro in contrast to Panc-1
(Fig. 4B).
When Panc-1 cells were implanted subcutaneously or ortho-
topically into mice, a strong increase of mRNA expression was
observed for CXCR3-A and CXCR-B (50-fold and 35-fold
increase respectively, Fig. 4C). Positive immunoreactivity for
CXCR3 was also evidenced in these tumors (Fig. 4D). For MIA
PaCa-2 cells, after in vivo implantation, CXCR3-B was highly
expressed (Fig. 4C and D) and much higher than in vitro (copy
number ratio CXCR3/HPRT in vivo: 14, 687 # 0.011 versus 5.39
" 10&4 # 1.1 " 10&4in vitro). Metastatic foci were also positive
for CXCR3. On the contrary, BxPC3 cells do not signiﬁcantly
express CXCR3-A and -B in vivo.
Seventy PDAC samples included in TMAs were then analyzed.
The cytoplasmic and nuclear scores ranged from 20 to 300
(median: 175) and from 0 to 300 (median: 175), respectively
(Fig. 4E). Twenty-two (31%) of the tumors presented a membra-
nous staining pattern, some of which had cytoplasmic staining
(Fig. 4E). CXCR3 nuclear andmembranous expression correlated
positively with tumor size (P ¼ 0.02 and P ¼ 0.06, respectively).
CXCR3 membranous expression correlated with the presence of
perineural invasion (P ¼ 0.04).
We furthermore performed an in silico analysis of CXCR3
expression using the Ramaswamy multicancer set (22) and the
Bucholz pancreas dataset (Supplementary Fig. S4; ref. 23). In the
Ramaswamy dataset, high expression of CXCR3 could be evi-
denced inPDAC, aﬁnding that is further conﬁrmed in theBucholz
dataset where expression is also signiﬁcantly increased in PDAC
compared with normal pancreas.
In vitro and in vivo functional studies
In vitro effects of CXCL4L1. CXCL4L1 inhibited endothelial cell
but not BXPC3 cell proliferation (Fig. 5A and B, left; ref. 3).
Invasion of endothelial cells, but not that of BxPC3 cells, was
signiﬁcantly inhibited byCXCL4L1 (Fig. 5A,middle, andB, right).
No effect on apoptosis on either tumor or endothelial cells was
seen (Supplementary Fig. S5).
We veriﬁed, in addition, CXCR3 expression in HUVECs, which
is indeed signiﬁcantly expressed (Fig. 5A, right).
We next compared the role of CXCL4L1 in another pancreatic
cancer cell line, Panc-1 cells, which, in contrast to BxPC3 cells, do
express CXCR3 protein (Fig. 4C and D). This cell line already
expresses CXCL4L1 in cell culture (Fig. 1E). Blocking by either
CXCL4L1mAbor siRNA against CXCL4L1 aswell as CXCR3 led to
the inhibition of cell proliferation (Fig. 5C). Combining blockade
by MabL1 and CXCR3 siRNA further decreased cell proliferation.
This indicates that CXCL4L1 is a positive regulator of Panc-1
growth and that CXCR3 is also involved in the growth-promoting
activity.
As Panc-1 cells express CXCR3, we wanted to investigate
whether signaling induced by CXCL4L1 is modulated (Fig. 5D).
Indeed, ERK phosphorylation was increased after CXCL4L1
treatment. This increase could be blocked by U1026, a speciﬁc
inhibitor of MAP kinases.
Effect of endogenous CXCL4L1 on tumor development. RAG-g/c
mice were inoculated subcutaneously with BxPC3 or Panc-1 cells
and then treated with MabL1 antibody. Prior to the tumor
experiments, we characterize the half-life, clearance, and tumor
targeting of this antibody in mice (Supplementary Fig. S6A–S6E;
Supplementary Materials and Methods).
We next investigated whether MabL1 was able to target
tumor lesions in mice (Fig. 6A–F). BxPC3 cells were injected
in the spleen (1 " 106 cells) in mice. Tumors usually occurred
at 2 months postinjection. Infrared dye–labeled MabL1 anti-
body was administered by intravenous injection. Imaging of
organs revealed targeting of the antibody to metastatic lesions
in the lung and kidney.
In BxPC3 tumor xenografts, injection of MabL1 in mice
yielded an increase in tumor growth (Fig. 7A). MabL1 (25 mg)
was injected twice a week, and tumor growth was monitored
during a 2-month period. Forty-eight days after implantation,
tumor size increased by 2-fold in MabL1-treated animals when
compared with nontreated controls (2,612 mm3 in MabL1-
treated mice vs. 1,184 mm3 in control mice). Tumor weight was
also increased after antibody treatment (Fig. 7B). The kinetics of
tumor growth in MabL1-treated mice was 81.5 mm3 per day in
comparison with 34.9 mm3 per day in untreated controls. An
increase in the density of small vessels was observed in treated
tumors compatible with an angiogenesis-related effect (Fig. 7C
and D). The vessel increase in MabL1-treated tumor was not
accompanied by variation in NG2þ cell coverage (Fig. 7E).
In Panc-1 tumor xenografts, the administration of CXCL4L1
antibody had an opposite effect (Fig. 7F and G). Using the same
treatment protocol as for BxPC3 cells, administration of the
MabL1 antibody led to a reduction of tumor size in both subcu-
taneously and orthotopically implanted tumors (subcutaneous
implantation: 1,140 mm3 in MabL1-treated mice vs. 1,845 mm3
in control mice; orthotopic implantation: 2.8eþ06 cpm in
MabL1-treated mice vs. 1.25eþ07 cpm in control mice). Tumor
weight was reduced in both orthotopic and subcutaneous tumors
in the presence of MabL1 (Fig. 7H). Lung metastasis as measured
by the presence of hS16 mRNA was signiﬁcantly reduced in
orthotopic tumors (Fig. 7I). Furthermore, proliferation measured
by hMIB1 expression and Ki67 staining was decreased in ortho-
topic tumors after MabL1 injection (Fig. 7J and L). However, no
effect on vessel quantity as measured by PCAM1 expression was
seen (Fig. 7K and L).
Taken together, these results point to an opposite effect of
CXCL4L1 in these two pancreatic tumor cell lines, which corre-
lates with the presence of CXCR3 on tumor cells.
We next performed qPCR analysis for PECAM1 in Panc-1 and
MIA PaCa-2 tumor samples (Supplementary Fig. S7A). Panc-1
cells express CXCL4L1 contrary to MIA PaCa-2 cells. Supple-
mentary Figure S7A clearly shows that PECAM1 levels were
much reduced in Panc1 in comparison with MIA PaCa-2 cells
(6.16-fold), and this was inversely correlated with CXCL4L1
expression. Furthermore, we analyzed mouse CXCR3 expres-
sion in both tumor types (Supplementary Fig. S7B). Primers are
only detecting stroma-derived CXCR3 but no tumor-derived
CXCR3. As seen in the ﬁgure, this correlated well with PECAM1
expression and inversely with CXCR3 expression (6.16-fold in
both cases). In addition, the ﬁgure shows that CXCL4L1 is 11
times more expressed in Panc-1 tumors when compared with
healthy control pancreas (Supplementary Fig. S7B).
Modulation of CXCR3 in PDAC cells
To study the impact of CXCR3-A, we focused on MIA PaCa-2
cells, as Panc-1 cell knockdown or overexpression was unsuccess-
ful. CXCR3-A was cloned into pGFPN2 vector and stable clones
Quemener et al.
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Functional studies of CXCL4L1 in pancreatic adenocarcinoma and endothelial cells. A, activity of recombinant GST-CXCL4L1 and cleaved CXCL4L1 on HUVEC
proliferation after 48 hours (left). Endothelial cells cultured with FGF2 (20 ng/mL) and 50 ng/mL of recombinant proteins in the presence of MabL1 (10 mg/mL)
or of an IgG control antibody. Effect of recombinant CXCL4L1 (GST-CXCL4L1) on FGF2-stimulated (10 ng/mL) proliferation or invasion of HUVECs
(proliferation, left; invasion, middle). CXCR3 protein expression assessed by Western blot analysis in HUVEC cells (right). Vinculin was used as a loading
control. B, BXPC3 cells (proliferation, left; invasion, right) in the presence of CXCL4L1. C, effect of CXCL4L1 and CXCR3 knockdown or antibody treatment on
the proliferation of Panc-1 cells. Cells transfected with the speciﬁc siRNAs or control siRNAs, grown in complete medium, and treated or untreated
with the monoclonal anti-CXCL4L1 antibody over 120 hours. Results as average # SEM of three independent experiments done in triplicates; $$ P < 0.01;
$ , P < 0.05. D, effect of CXCL4L1 on signaling in Panc-1 cells. Cells stimulated with minimal medium from CXCL4L1-infected cells (MIA PaCa-2)
containing >300 ng/mL CXCL4L1 and ERK phosphorylation measured by Western blotting with and without a speciﬁc inhibitor of MAP kinases (U1026,
50 mmol/L). 0% M, serum-free medium; CM, complete medium.
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were isolated. Very high expression levels were observed (copy
number 574,943 for CXCR3-A/HPRT; Supplementary Fig. S8A).
Cells were also positive by immunodetection (Supplementary
Fig. S8B).
We next investigated the functionality of CXCR3 in the
condition of chronic stimulation (Supplementary Figs. S8C
and S9A–S9C). Only CXCL4L1 produced in Hek cells (Hek-
CXCL4L1) stimulated proliferation of MIA PaCa-2-CXCR3
cells. We veriﬁed that this effect is dependent on CXCL4L1
and CXCR3 by using MabL1 and SCH546738, a speciﬁc
high-afﬁnity antagonist of CXCR3, which demonstrated that
this is indeed the case (Supplementary Fig. S9B). We also
veriﬁed the signaling ability and demonstrated that chemo-
kine stimulation induced ERK phosphorylation (Supplemen-
tary Fig. S9C).
Orthotopic implantation of MIA PaCa-2-CXCR3 cells did not
show a difference in tumor weight when compared with control
vector-transfected MIA PaCa-2 cells at sacriﬁce (day 34 after
implantation; Supplementary Fig. S9D). However, the number
of lungmetastaseswas increased [humanHPRT-1/mouseHPRT-1
by qPCR; 3.5 # 0.86 (controls) versus 7.3 # 1.46 (CXCR3-A
overexpressors; Supplementary Fig. S9E)]. AsMIAPaCa-2 cells did
not show signiﬁcant elevation of CXCL4L1 expression when
compared with BxPC3 or Panc-1 cells, we did not perform
inhibition studies using the blocking antibody (MabL1). Despite
the fact that tumor weight was not modiﬁed, changes in hypoxia
signature and MMP9 were observed (Supplementary Fig. S9F) in
cells that overexpress CXCR3-A. This indicates that CXCR3 has
in vivo intrinsically, in the absence of CXCL4L1, prometastatic
abilities in pancreatic tumor cells.
Discussion
Our data show that tumor cells upregulate CXCL4L1
expression when placed in a suitable microenvironment.
Myoﬁbroblasts mimic the in vivo microenvironment and were
able to induce expression of CXCL4L1. Among potential
factors, IL1b was reported to induce promoter demethyl-
ation after long-term exposure (21). However, IL1b did not
induce CXCL4L1 expression in PDAC cells after short- or
long-term exposure. Microparticles from myoﬁbroblast-con-
ditioned medium induced CXCL4L1 expression in tumor
cells. However, the effect of the microparticle preparation
was much less when compared with chronic exposure in the
coculture system. This indicates that a yet nonidentiﬁed
soluble factor is involved in the induction of CXCL4L1
expression in PDAC cells.
We demonstrated that epigenetic modiﬁcations through
methylation play a critical role in the induction of CXCL4L1
in tumor cells similar to what has been reported for some other
angiogenic factors, receptors, or chemokines, such as maspin
(24), intercellular adhesion molecule-1 (ICAM-1) (25), or
CXCL12 (SDF1; refs. 26, 27). We found that human PDAC
tumors are usually hypomethylated on all eight methylation
sites of the CpG island identiﬁed, of which two are involved in
the induction of CXCL4L1 expression. This is in contrast to
many genes where methylation follows tumor progression.
However, hypomethylation during tumor progression has also
been reported for other genes, including urokinase-type plas-
minogen activator (28), maspin (29), or matrix metalloprotei-
nases (30), which is in line with our ﬁndings.
Figure 6.
Targeting of monoclonal MabL1 to tumor lesion in mice. Antibodies labeled with IRDye (MabL1-IRdye) and injected into the tail vein in tumor-bearing mice.
Six days after Mabl1-IRdye injection, tissues were removed after sacriﬁce and imaged on the Odyssey Imaging System, frozen, cut into 40-mm sections,
and imaged again. Lesions targeted by MabL1 are shown in the lung (A–C) and kidney (D–F). C and F depict images of frozen sections.
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Effect of CXCL4L1 blockade on in vivo pancreatic tumor development. A, tumor development in subcutaneously implanted BxPC3 cells (n ¼ 12/group)
and followed by caliper measurements in MabL1 or control antibody–treated animals. Treated tumors were signiﬁcantly larger ($$ , P < 0.01). B, on the day
of sacriﬁce, tumors were excised and weighted ($$ , P < 0.01). C, immunoﬂuorescence staining for CD31 and NG2 on subcutaneous BxPC3 tumor section
from control and MabL1-treated mice. D, quantiﬁcation of vessel density grouped in small (<10 mm2), medium (10–100 mm2), or large CD31þ vessels (>100 mm2;
n ¼ 5 tumors/group, 10 pictures/tumor). MabL1-treated mice have signiﬁcantly more small-diameter vessels in tumors compared with untreated controls
($ , P < 0.05). E, quantiﬁcation of SMC coverage. F, Panc-1 cells implanted subcutaneously or orthotopically by direct intrapancreatic injection in
Rag2 g/c mice and treated with MabL1 or with the control antibody. MabL1-treated mice with subcutaneously implanted cells had signiﬁcantly smaller tumors
($$ , P < 0,01). G, bioluminescent imaging on orthotopic PANC-1-LucFireﬂy tumors using the Photon Imager (Biospace). Analysis by M3Vision software and
represented as total ﬂux measurements in count per minute. H, weights recorded from the excised tumors at sacriﬁce day 75 and 92 for orthotopic and
subcutaneous tumors, respectively ($$, P < 0,01; $ , P < 0.05). I, quantiﬁcation of lung metastasis in subcutaneously and orthotopically implanted mice by qRT-PCR
for the human S16 gene (n ¼ 10 lungs/group; $ , P < 0.05). mHPRT1, housekeeping gene. J and K, qRT-PCR analyses for human MIB1 (J) and mouse PECAM1 (K)
in tumors ($, P < 0.05). L, immunoﬂuorescence staining for mouse CD31 and human Ki67 on orthotopic tumor sections. Scale bar, 50 mm. Error bars, SEM.
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It is to emphasize that CXCL4L1 or CXCL4 expression is not
uniform for all pancreatic carcinoma cell lines tested. When
CXCL4L1 or CXCL4 were analyzed in pancreatic carcinoma
cells in vitro or after tumor implantation, two of the cell lines
(BxPC3 and Panc-1) expressed increased levels of CXCL4L1
but not of CXCL4 in vivo. On the contrary, another cell line
(Mia PaCa-2) overexpressed already in vitro CXCL4 but not
CXCL4L1, and this was further increased in tumors generated
after implantation in mice. Thus, CXCL4 may also have a role in
PDAC physiopathology.
Expression of CXCL4L1 was also evidenced in other tumor
types, such as colon tumors or esophageal cancer (31). Endome-
triosis-associated ovarian cancer seems to express decreased levels
of CXCL4L1 (and CXCL4) in comparison with normal endome-
trium and endometriosis lesion, but only in tumor-associated
macrophages (32).
Anti-CXCL4L1 antibodieswere able to targetmetastatic lesions.
This suggests that CXCL4L1 could be used for tumor targeting.
However,mice donot expressCXCL4L1, and inhumans, targeting
of CXCL4L1 may also affect normal cells, which would not be
appropriate for tumor-targeting applications. CXCL4L1 diffuses
much better than CXCL4 and, therefore, may not stay within the
tumor tissue. Thus, further experiments are needed to validate
CXCL4L1 for tumor-targeting approaches.
Functional data indicate that CXCL4L1 has no effect on
proliferation, migration, or survival when tumor cells do not
express CXCR3 protein, as is the case for BxPC3. Furthermore,
signiﬁcant effects on endothelial cell proliferation, migration,
survival or tube formation, and cell signaling were observed
after CXCL4L1 stimulation, which is in agreement with previ-
ous studies. Endothelial cell–expressed CXCR3 has been pro-
posed to mediate the antiangiogenic effects of CXCL4 and
CXCL4L1 (6, 33). Alternatively, CXCL4L1 may bind to an, as
yet, unknown receptor.
Wenext investigated the role of endogenousCXCL4L1 in PDAC
development. Transgenic mice models using conditional expres-
sion of mutant K-ras and p53 allele or TGFb receptor seem to
better recapitulate the multistage PDAC developmental process
(34, 35) than implant models. However, CXCL4L1 is not present
in mice, and thus, experiments aimed at blocking endogenous
CXCL4L1 cannot be performed in these models.
In BxPC3 tumor xenografts, which do not express CXCR3
protein, blockade of endogenousCXCL4L1 resulted in an increase
in tumor development. This is in agreement with an effect on the
tumor stroma. In contrast, in Panc-1 tumor xenografts, which
express high levels of CXCR3, the blockade of endogenous
CXCL4L1 led to a decreased tumor development. Furthermore,
we observed that CXCR3-A is mainly upregulated in Panc-1 cells
in vivo. This is reinforced by functional studies that show that
CXCR3 knockdown diminishes Panc-1 cell proliferation. The
observation that tumors cells, which express CXCR3-A, exhibit
an increase in tumor cell survival and proliferation is in line with
our data (36). Furthermore, CXCR3 has intrinsically pro-meta-
static activity.
All in all, our work establishes CXCL4L1 as a novel regulator of
pancreatic tumor development that not only acts on the tumor
microenvironment but also directly on tumor cells themselves.
Expression of CXCL4L1 in tumor cells is controlled by stroma–
tumor cell interactions and by epigenetic regulations. Further
work is required to fully understand the speciﬁc microenviron-
mental and epigenetic mechanisms that regulate CXCL4L1
expression in tumor cells.
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